Clinical Trial: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07183189) titled 'A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC' on Sept. 12.

Brief Summary: This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naive subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: SHR-A2009 ; Aumolertinib

SHR-A2009 admi...